{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:14:01Z","timestamp":1788984841378,"version":"build-2803163510"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13555-026-01846-3","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:00:40Z","timestamp":1783393240000},"page":"4249-4271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pediatric Psoriasis: Comorbidities, Treatment Challenges and Unmet Needs"],"prefix":"10.1007","volume":"16","author":[{"given":"Marc","family":"Hern\u00e1ndez-Santacana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Balado-Sim\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Mansilla-Polo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9265-1019","authenticated-orcid":false,"given":"Josep","family":"Riera-Monroig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"1846_CR1","volume-title":"Global report on psoriasis","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Global report on psoriasis. Geneva: World Health Organization; 2016."},{"issue":"1","key":"1846_CR2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jaad.2019.08.049","volume":"82","author":"A Menter","year":"2020","unstructured":"Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, et al. Joint American Academy of Dermatology\u2013National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161\u2013201. https:\/\/doi.org\/10.1016\/j.jaad.2019.08.049.","journal-title":"J Am Acad Dermatol"},{"key":"1846_CR3","doi-asserted-by":"publisher","unstructured":"Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: A population-based study. Archives of Dermatology. 2005;141(12). https:\/\/doi.org\/10.1001\/archderm.141.12.1537.","DOI":"10.1001\/archderm.141.12.1537"},{"key":"1846_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12205","author":"D Matusiewicz","year":"2014","unstructured":"Matusiewicz D, Koerber A, Schadendorf D, Wasem J, Neumann A. Childhood psoriasis - an analysis of German health insurance data. Pediatr Dermatol. 2014. https:\/\/doi.org\/10.1111\/pde.12205.","journal-title":"Pediatr Dermatol"},{"key":"1846_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0294-9","author":"M Relvas","year":"2017","unstructured":"Relvas M, Torres T. Pediatric psoriasis. Am J Clin Dermatol. 2017. https:\/\/doi.org\/10.1007\/s40257-017-0294-9.","journal-title":"Am J Clin Dermatol"},{"key":"1846_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17049","author":"A Morita","year":"2024","unstructured":"Morita A, Saeki H. Pediatric psoriasis: understanding pathological conditions and advances in treatment. J Dermatol. 2024. https:\/\/doi.org\/10.1111\/1346-8138.17049.","journal-title":"J Dermatol"},{"key":"1846_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.13907","author":"L Eisert","year":"2019","unstructured":"Eisert L, Augustin M, Bach S, Dittmann M, Eiler R, F\u00f6lster\u2010Holst R, et al. S2k guidelines for the treatment of psoriasis in children and adolescents \u2013 short version part 1. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2019. https:\/\/doi.org\/10.1111\/ddg.13907.","journal-title":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft"},{"key":"1846_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2059051","author":"AA Hebert","year":"2022","unstructured":"Hebert AA, Browning J, Kwong PC, Duarte AM, Price HN, Siegfried E. Managing pediatric psoriasis: update on treatments and challenges\u2014a review. J Dermatol Treat. 2022. https:\/\/doi.org\/10.1080\/09546634.2022.2059051.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"1846_CR9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jaad.2017.05.017","volume":"77","author":"KM Cordoro","year":"2017","unstructured":"Cordoro KM, Hitraya-Low M, Taravati K, Sandoval PM, Kim E, Sugarman J, et al. Skin-infiltrating, interleukin-22\u2013producing T cells differentiate pediatric psoriasis from adult psoriasis. J Am Acad Dermatol. 2017;77(3):417\u201324. https:\/\/doi.org\/10.1016\/j.jaad.2017.05.017.","journal-title":"J Am Acad Dermatol"},{"key":"1846_CR10","doi-asserted-by":"publisher","DOI":"10.1159\/000450826","author":"J Gonzalez","year":"2017","unstructured":"Gonzalez J, Cunningham K, Perlmutter J, Gottlieb A. Systematic review of health-related quality of life in adolescents with psoriasis. Dermatology. 2017. https:\/\/doi.org\/10.1159\/000450826.","journal-title":"Dermatology"},{"key":"1846_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2011.01489.x","author":"MEA De Jager","year":"2011","unstructured":"De Jager MEA, De Jong EMGJ, Evers AWM, Van De Kerkhof PCM, Seyger MMB. The burden of childhood psoriasis. Pediatr Dermatol. 2011. https:\/\/doi.org\/10.1111\/j.1525-1470.2011.01489.x.","journal-title":"Pediatr Dermatol"},{"key":"1846_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10280.x","author":"RB Warren","year":"2011","unstructured":"Warren RB, Kleyn CE, Gulliver WP. Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. Br J Dermatol. 2011. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10280.x.","journal-title":"Br J Dermatol"},{"key":"1846_CR13","doi-asserted-by":"publisher","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA\u2014a scale for the quality assessment of narrative review articles. Research Integrity and Peer Review. 2019;4(1). https:\/\/doi.org\/10.1186\/s41073-019-0064-8.","DOI":"10.1186\/s41073-019-0064-8"},{"issue":"4","key":"1846_CR14","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/pde.14208","volume":"37","author":"K Phan","year":"2020","unstructured":"Phan K, Lee G, Fischer G. Pediatric psoriasis and association with cardiovascular and metabolic comorbidities: systematic review and meta-analysis. Pediatr Dermatol. 2020;37(4):661\u20139. https:\/\/doi.org\/10.1111\/pde.14208.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"1846_CR15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1001\/jamadermatol.2013.1078","volume":"149","author":"AS Paller","year":"2013","unstructured":"Paller AS, Mercy K, Kwasny MJ, Eng Choon S, Cordoro KM, Girolomoni G, et al. Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatol. 2013;149(2):166\u201376. https:\/\/doi.org\/10.1001\/jamadermatol.2013.1078.","journal-title":"JAMA Dermatol"},{"key":"1846_CR16","doi-asserted-by":"publisher","unstructured":"Boccardi D, Menni S, Vecchia C La, Nobile M, Decarli A, Volpi G, et al. Overweight and childhood psoriasis. British Journal of Dermatology. 2009. p. 484\u2013486. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09276.x.","DOI":"10.1111\/j.1365-2133.2009.09276.x"},{"issue":"3","key":"1846_CR17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.clindermatol.2014.12.006","volume":"33","author":"I Gutmark-Little","year":"2015","unstructured":"Gutmark-Little I, Shah KN. Obesity and the metabolic syndrome in pediatric psoriasis. Clin Dermatol. 2015;33(3):305\u201315. https:\/\/doi.org\/10.1016\/j.clindermatol.2014.12.006.","journal-title":"Clin Dermatol"},{"key":"1846_CR18","doi-asserted-by":"publisher","unstructured":"Osier E, Wang AS, Tollefson MM, Cordoro KM, Daniels SR, Eichenfield A, et al. Pediatric psoriasis comorbidity screening guidelines. JAMA Dermatology. 2017. p. 698\u2013704. https:\/\/doi.org\/10.1001\/jamadermatol.2017.0499.","DOI":"10.1001\/jamadermatol.2017.0499"},{"issue":"3","key":"1846_CR19","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ad.2024.06.007","volume":"116","author":"A Vicente","year":"2025","unstructured":"Vicente A, P\u00e9rez-Ferriols A, Batalla A, Garc\u00eda-Fernandez L, P\u00e9rez B, Eiris N, et al. Documento de consenso del Grupo Espa\u00f1ol de Psoriasis (GPS) y del grupo Espa\u00f1ol de Dermatolog\u00eda Pedi\u00e1trica (GEDP) de la Academia Espa\u00f1ola de Dermatolog\u00eda y Venereolog\u00eda (AEDV) sobre el manejo de la psoriasis pedi\u00e1trica. Actas Dermosifiliogr. 2025;116(3):254\u201380. https:\/\/doi.org\/10.1016\/j.ad.2024.06.007.","journal-title":"Actas Dermosifiliogr"},{"issue":"2","key":"1846_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.arcped.2018.12.005","volume":"26","author":"A Badaoui","year":"2019","unstructured":"Badaoui A, Tounian P, Mah\u00e9 E. Psoriasis and metabolic and cardiovascular comorbidities in children: a systematic review. Arch Pediatr. 2019;26(2):86\u201394. https:\/\/doi.org\/10.1016\/j.arcped.2018.12.005.","journal-title":"Arch Pediatr"},{"issue":"6","key":"1846_CR21","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jaad.2017.08.034","volume":"77","author":"L Kwa","year":"2017","unstructured":"Kwa L, Kwa MC, Silverberg JI. Cardiovascular comorbidities of pediatric psoriasis among hospitalized children in the United States. J Am Acad Dermatol. 2017;77(6):1023\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2017.08.034.","journal-title":"J Am Acad Dermatol"},{"issue":"23","key":"1846_CR22","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1056\/NEJMoa031049","volume":"350","author":"R Weiss","year":"2004","unstructured":"Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;350(23):2362\u201374. https:\/\/doi.org\/10.1056\/NEJMoa031049.","journal-title":"N Engl J Med"},{"key":"1846_CR23","doi-asserted-by":"publisher","unstructured":"Kara T, Topkarc\u0131 Z, Y\u0131lmaz S, Akaltun \u0130, Erdo\u011fan B. Pediatric patients with psoriasis and psychiatric disorders: premorbidity and comorbidity in a case-control study. Journal of Dermatological Treatment. 2019;30(2). https:\/\/doi.org\/10.1080\/09546634.2018.1476653.","DOI":"10.1080\/09546634.2018.1476653"},{"key":"1846_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15095","author":"T Todberg","year":"2017","unstructured":"Todberg T, Egeberg A, Jensen P, Gislason G, Skov L. Psychiatric comorbidities in children and adolescents with psoriasis: a population-based cohort study. Br J Dermatol. 2017. https:\/\/doi.org\/10.1111\/bjd.15095.","journal-title":"Br J Dermatol"},{"key":"1846_CR25","doi-asserted-by":"publisher","unstructured":"Kimball AB, Wu EQ, Gu\u00e9rin A, Yu AP, Tsaneva M, Gupta SR, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. Journal of the American Academy of Dermatology. 2012;67(4). https:\/\/doi.org\/10.1016\/j.jaad.2011.11.948.","DOI":"10.1016\/j.jaad.2011.11.948"},{"issue":"3","key":"1846_CR26","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00403-022-02377-5","volume":"315","author":"WK Hung","year":"2023","unstructured":"Hung WK, Tung TH, Wang TY, Liao SC, Chi CC. Risk for incident suicidality among psoriasis patients: a systematic review and meta-analysis. Arch Dermatol Res. 2023;315(3):455\u201365. https:\/\/doi.org\/10.1007\/s00403-022-02377-5.","journal-title":"Arch Dermatol Res"},{"key":"1846_CR27","doi-asserted-by":"publisher","unstructured":"Kroenke K, Spitzer RL, Williams JBW, L\u00f6we B. An ultra-brief screening scale for anxiety and depression: The PHQ-4. Psychosomatics. 2009;50(6). https:\/\/doi.org\/10.1016\/s0033-3182(09)70864-3.","DOI":"10.1016\/s0033-3182(09)70864-3"},{"key":"1846_CR28","doi-asserted-by":"publisher","unstructured":"Yang A, Cheng B, Seyger MMB, Murphy R, Stoll ML, Cordoro KM, et al. The Burden of Pediatric Psoriasis: A Systematic Review. American Journal of Clinical Dermatology. 2025. p. 695\u2013710. https:\/\/doi.org\/10.1007\/s40257-025-00965-5.","DOI":"10.1007\/s40257-025-00965-5"},{"key":"1846_CR29","doi-asserted-by":"publisher","unstructured":"Manzoni APD da S, Weber MB, Nagatomi AR da S, Pereira RL, Townsend RZ, Cestari TF. Assessing depression and anxiety in the caregivers of pediatric patients with chronic skin disorders. Anais Brasileiros de Dermatologia. 2013;88(6). https:\/\/doi.org\/10.1590\/abd1806-4841.20131915.","DOI":"10.1590\/abd1806-4841.20131915"},{"key":"1846_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.07.001","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P. The Epidemiology of Psoriatic Arthritis. Rheumatic Disease Clinics of North America. 2015. https:\/\/doi.org\/10.1016\/j.rdc.2015.07.001.","journal-title":"Rheumatic Disease Clinics of North America"},{"key":"1846_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e328348b278","author":"ML Stoll","year":"2011","unstructured":"Stoll ML, Punaro M. Psoriatic juvenile idiopathic arthritis: A tale of two subgroups. Curr Opin Rheumatol. 2011. https:\/\/doi.org\/10.1097\/BOR.0b013e328348b278.","journal-title":"Curr Opin Rheumatol"},{"key":"1846_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1396-0296.2004.04039.x","author":"D Lewkowicz","year":"2004","unstructured":"Lewkowicz D, Gottlieb AB. Pediatric psoriasis and psoriatic arthritis. Dermatol Ther. 2004. https:\/\/doi.org\/10.1111\/j.1396-0296.2004.04039.x.","journal-title":"Dermatol Ther"},{"key":"1846_CR33","doi-asserted-by":"publisher","unstructured":"Alinaghi F, Tekin HG, Burisch J, Wu JJ, Thyssen JP, Egeberg A. Global Prevalence and Bidirectional Association between Psoriasis and Inflammatory Bowel Disease-A Systematic Review and Meta-analysis. Journal of Crohn\u2019s and Colitis. 2020. p. 351\u2013360. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz152.","DOI":"10.1093\/ecco-jcc\/jjz152"},{"issue":"8","key":"1846_CR34","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1007\/s13555-022-00761-7","volume":"12","author":"M Sticherling","year":"2022","unstructured":"Sticherling M, McPherson T, de Lucas LR, Costanzo A, Reed C, Artime E, et al. Patient Characteristics and Treatment Patterns in European Pediatric Patients with Psoriasis: A Real-World. Cross-Sectional Study Dermatology and Therapy. 2022;12(8):1793\u2013808. https:\/\/doi.org\/10.1007\/s13555-022-00761-7.","journal-title":"Cross-Sectional Study Dermatology and Therapy"},{"key":"1846_CR35","doi-asserted-by":"publisher","unstructured":"Frangos JE, Kimball AB. Clobetasol propionate emollient formulation foam in the treatment of corticosteroid-responsive dermatoses. Expert Opinion on Pharmacotherapy. 2008;9(11). https:\/\/doi.org\/10.1517\/14656566.9.11.2001.","DOI":"10.1517\/14656566.9.11.2001"},{"key":"1846_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70319-W","author":"G Herz","year":"1991","unstructured":"Herz G, Blum G, Yawalkar S. Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis. J Am Acad Dermatol. 1991. https:\/\/doi.org\/10.1016\/0190-9622(91)70319-W.","journal-title":"J Am Acad Dermatol"},{"key":"1846_CR37","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2110071","author":"M Chung","year":"2022","unstructured":"Chung M, Yeroushalmi S, Hakimi M, Bartholomew E, Liao W, Bhutani T. A critical review of halobetasol propionate foam (0.05%) as a treatment option for adolescent plaque psoriasis. Expert Rev Clin Immunol. 2022. https:\/\/doi.org\/10.1080\/1744666X.2022.2110071.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"1846_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40272-023-00592-9","volume":"26","author":"E Lie","year":"2024","unstructured":"Lie E, Choi M, Wang SP, Eichenfield LF. Topical Management of Pediatric Psoriasis: A Review of New Developments and Existing Therapies. Pediatr Drugs. 2024;26(1):9\u201318. https:\/\/doi.org\/10.1007\/s40272-023-00592-9.","journal-title":"Pediatr Drugs"},{"issue":"11","key":"1846_CR39","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1001\/jamadermatol.2017.3029","volume":"153","author":"IMGJ Bronckers","year":"2017","unstructured":"Bronckers IMGJ, Seyger MMB, West DP, Lara-Corrales I, Tollefson M, Tom WL, et al. Safety of systemic agents for the treatment of pediatric psoriasis. JAMA Dermatol. 2017;153(11):1147\u201357. https:\/\/doi.org\/10.1001\/jamadermatol.2017.3029.","journal-title":"JAMA Dermatol"},{"key":"1846_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70108","author":"Y Miao","year":"2025","unstructured":"Miao Y, Beauchet A, Piram M, McPherson T, Torres T, Yesli Y, et al. Drug survival of systemic treatments for severe paediatric psoriasis: An international retrospective study. J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.70108.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1846_CR41","doi-asserted-by":"publisher","DOI":"10.4137\/cmped.s8045","author":"IL Corrales","year":"2013","unstructured":"Corrales IL, Ramnahne S, Lansang P. Treatment of Childhood Psoriasis with Phototherapy and Photochemotherapy. Clin Med Insights Pediatr. 2013. https:\/\/doi.org\/10.4137\/cmped.s8045.","journal-title":"Clin Med Insights Pediatr"},{"key":"1846_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/pde.13382","author":"LF Eichenfield","year":"2018","unstructured":"Eichenfield LF, Paller AS, Tom WL, Sugarman J, Hebert AA, Friedlander SF, et al. Pediatric psoriasis: Evolving perspectives. Pediatr Dermatol. 2018. https:\/\/doi.org\/10.1111\/pde.13382.","journal-title":"Pediatr Dermatol"},{"key":"1846_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.896550","author":"XC Cai","year":"2022","unstructured":"Cai XC, Ru Y, Liu L, Sun XY, Zhou YQ, Luo Y, et al. Efficacy and safety of biological agents for the treatment of pediatric patients with psoriasis: A bayesian analysis of six high-quality randomized controlled trials. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.896550.","journal-title":"Front Immunol"},{"key":"1846_CR44","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17002","author":"C Bodemer","year":"2021","unstructured":"Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol. 2021. https:\/\/doi.org\/10.1111\/jdv.17002.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1846_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19147","author":"AS Paller","year":"2020","unstructured":"Paller AS, Seyger MMB, Alejandro Magari\u00f1os G, Bagel J, Pinter A, Cather J, et al. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 2020. https:\/\/doi.org\/10.1111\/bjd.19147.","journal-title":"Br J Dermatol"},{"key":"1846_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19018","author":"S Philipp","year":"2020","unstructured":"Philipp S, Menter A, Nikkels AF, Barber K, Landells I, Eichenfield LF, et al. Ustekinumab for the treatment of moderate\u2010to\u2010severe plaque psoriasis in paediatric patients (\u2265 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open\u2010label CADMUS Jr study. Br J Dermatol. 2020. https:\/\/doi.org\/10.1111\/bjd.19018.","journal-title":"Br J Dermatol"},{"key":"1846_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-016-0095-3","author":"R Leuvenink","year":"2016","unstructured":"Leuvenink R, Aeschlimann F, Baer W, Berthet G, Cannizzaro E, Hofer M, et al. Clinical course and therapeutic approach to varicella zoster virus infection in children with rheumatic autoimmune diseases under immunosuppression. Pediatr Rheumatol. 2016. https:\/\/doi.org\/10.1186\/s12969-016-0095-3.","journal-title":"Pediatr Rheumatol"},{"key":"1846_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4367-9","author":"D Aygun","year":"2019","unstructured":"Aygun D, Sahin S, Adrovic A, Barut K, Cokugras H, Camc\u0131oglu Y, et al. The frequency of infections in patients with juvenile idiopathic arthritis on biologic agents: 1-year prospective study. Clin Rheumatol. 2019. https:\/\/doi.org\/10.1007\/s10067-018-4367-9.","journal-title":"Clin Rheumatol"},{"key":"1846_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-020-00905-8","author":"N Toplak","year":"2020","unstructured":"Toplak N, Uziel Y. Vaccination for Children on Biologics. Curr Rheumatol Rep. 2020. https:\/\/doi.org\/10.1007\/s11926-020-00905-8.","journal-title":"Curr Rheumatol Rep"},{"key":"1846_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.01.037","author":"Y Uziel","year":"2020","unstructured":"Uziel Y, Moshe V, Onozo B, Kulcs\u00e1r A, Tr\u00f3bert-Sipos D, Akikusa JD, et al. Live attenuated MMR\/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: Multicenter, retrospective data collection. Vaccine. 2020. https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.037.","journal-title":"Vaccine"},{"key":"1846_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-017-2985-x","author":"AB Fortina","year":"2017","unstructured":"Fortina AB, Bardazzi F, Berti S, Carnevale C, Di Lernia V, El Hachem M, et al. Treatment of severe psoriasis in children: recommendations of an Italian expert group. Eur J Pediatr. 2017. https:\/\/doi.org\/10.1007\/s00431-017-2985-x.","journal-title":"Eur J Pediatr"},{"key":"1846_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00758-2","author":"K Peris","year":"2022","unstructured":"Peris K, Fortina AB, Bianchi L, Fabbrocini G, Gisondi P, Balato A, et al. Update on the management of pediatric psoriasis: an Italian consensus. Dermatology and Therapy. 2022. https:\/\/doi.org\/10.1007\/s13555-022-00758-2.","journal-title":"Dermatology and Therapy"},{"key":"1846_CR53","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.13936","author":"L Eisert","year":"2019","unstructured":"Eisert L, Augustin M, Bach S, Dittmann M, Eiler R, F\u00f6lster-Holst R, et al. S2k guidelines for the treatment of psoriasis in children and adolescents \u2013 short version part 2. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2019. https:\/\/doi.org\/10.1111\/ddg.13936.","journal-title":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft"},{"key":"1846_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.07.029","author":"MM Tollefson","year":"2010","unstructured":"Tollefson MM, Crowson CS, McEvoy MT, Maradit Kremers H. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010. https:\/\/doi.org\/10.1016\/j.jaad.2009.07.029.","journal-title":"J Am Acad Dermatol"},{"key":"1846_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339","author":"R Parisi","year":"2013","unstructured":"Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Investig Dermatol. 2013. https:\/\/doi.org\/10.1038\/jid.2012.339.","journal-title":"J Investig Dermatol"},{"key":"1846_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdrv.2024.12.008","author":"A Firek","year":"2025","unstructured":"Firek A, Castelo-Soccio L. Pediatric psoriasis: biologics and oral small molecule inhibitors in modern therapy. JAAD Reviews. 2025. https:\/\/doi.org\/10.1016\/j.jdrv.2024.12.008.","journal-title":"JAAD Reviews"},{"key":"1846_CR57","doi-asserted-by":"publisher","unstructured":"Boehncke WH, Boehncke S, Tobin AM, Kirby B. The \u2018psoriatic march\u2019: A concept of how severe psoriasis may drive cardiovascular comorbidity. Experimental Dermatology. 2011;20(4). https:\/\/doi.org\/10.1111\/j.1600-0625.2011.01261.x.","DOI":"10.1111\/j.1600-0625.2011.01261.x"},{"key":"1846_CR58","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkae130","author":"K Griffin","year":"2024","unstructured":"Griffin K, Pearce F, Packham J. A meta-analysis and systematic review of the use of transition tools for patients transitioning from paediatric to adult rheumatology services. Rheumatology Advances in Practice. 2024. https:\/\/doi.org\/10.1093\/rap\/rkae130.","journal-title":"Rheumatology Advances in Practice"},{"key":"1846_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.017","author":"KM Cordoro","year":"2017","unstructured":"Cordoro KM, Hitraya-Low M, Taravati K, Sandoval PM, Kim E, Sugarman J, et al. Skin-infiltrating, interleukin-22\u2013producing T cells differentiate pediatric psoriasis from adult psoriasis. J Am Acad Dermatol. 2017. https:\/\/doi.org\/10.1016\/j.jaad.2017.05.017.","journal-title":"J Am Acad Dermatol"},{"key":"1846_CR60","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12404","author":"L Zhang","year":"2016","unstructured":"Zhang L, Li Y, Yang X, Wei J, Zhou S, Zhao Z, et al. Characterization of Th17 and FoxP3+ Treg cells in paediatric psoriasis patients. Scand J Immunol. 2016. https:\/\/doi.org\/10.1111\/sji.12404.","journal-title":"Scand J Immunol"},{"key":"1846_CR61","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12425","author":"E Gallo","year":"2013","unstructured":"Gallo E, Cabaleiro T, Rom\u00e1n M, Solano-L\u00f3pez G, Abad-Santos F, Garc\u00eda-D\u00edez A, et al. The relationship between tumour necrosis factor (TNF)-\u03b1 promoter and IL12B\/IL-23R genes polymorphisms and the efficacy of anti-TNF-\u03b1 therapy in psoriasis: a case-control study. Br J Dermatol. 2013. https:\/\/doi.org\/10.1111\/bjd.12425.","journal-title":"Br J Dermatol"},{"key":"1846_CR62","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2017.3071","author":"I Raposo","year":"2017","unstructured":"Raposo I, Carvalho C, Bettencourt A, Da Silva BM, Leite L, Selores M, et al. Psoriasis pharmacogenetics: HLACw* 0602 as a marker of therapeutic response to ustekinumab. Eur J Dermatol. 2017. https:\/\/doi.org\/10.1684\/ejd.2017.3071.","journal-title":"Eur J Dermatol"},{"key":"1846_CR63","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2147\/ptt.s328460","volume":"12","author":"E Camela","year":"2022","unstructured":"Camela E, Potestio L, Ruggiero A, Ocampo-Garza SS, Fabbrocini G, Megna M. Towards personalized medicine in psoriasis: current progress. Psoriasis: Targets and Therapy. 2022;12:231\u201350. https:\/\/doi.org\/10.2147\/ptt.s328460.","journal-title":"Psoriasis: Targets and Therapy"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01846-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01846-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01846-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:21:36Z","timestamp":1788981696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01846-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":63,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1846"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01846-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Marc Hern\u00e1ndez-Santacana and Pablo Balado-Sim\u00f3 have received support for attending meetings from Abbvie, Almirall SA, Johnson & Johnson, Leo Pharma, Lilly and Sanofi, Miguel Mansilla-Polo has acted as a speaker for Novartis, UCB and Almirall and has received support for attending meetings from AbbVie, Johnson & Johnson, Leo Pharma, Lilly and Sanofi, Josep Riera-Monroig has acted as a consultant and\/or speaker for and\/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis: AbbVie, Almirall SA, Amgen, Bristol Myers Squibb, Johnson & Johnson, Leo-Pharma, Lilly, Novartis and UCB. Josep Riera-Monroig is an Editorial Board member for\n                      Dermatology and Therapy\n                      and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}